Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Inclusion Criteria: * Age: 18-65 years old; * Pathologically (including histology or cytology) confirmed nasopharyngeal carcinoma patients, with clinical staging T1-4N2-3M0 (according to the UICC/AJCC TNM staging system, 8th edition); * No prior systemic treatment (surgery, radiotherapy, chemotherapy, etc.); * At least one measurable lesion on imaging (as per RECIST criteria version 1.1); * ECOG Performance Status (PS): 0-1; * Expected survival ≥3 months; * Male subjects and women of childbearing potential must use contraception from the first dose of study medication until 24 weeks after the last dose of study medication; * Normal major organ function, with basic normal results in hematology, biochemistry, and coagulation tests; * The investigator believes that the treatment will provide a survival benefit. Exclusion Criteria: * Active, known, or suspected autoimmune disease; * Patients with hypertension that cannot be controlled to normal range despite antihypertensive medication (systolic BP \>160 mmHg, diastolic BP \>90 mmHg); * History of hereditary bleeding tendency or coagulation dysfunction. Any clinically significant bleeding symptoms within 12 weeks prior to screening, or cumulative bleeding over 50 ml in 24 hours; * Unwell-controlled cardiac clinical symptoms or diseases; * Interstitial lung disease, drug-induced pneumonia, steroid-treated radiation pneumonitis, active pneumonia with symptoms, or severe pulmonary dysfunction; * Active hepatitis B (HBV DNA ≥2000 IU/mL or 10\^4 copies/mL), hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection of the assay); * Allergy to any of the study drugs; * Pregnant or breastfeeding women; * Any other factors that, in the investigator's judgment, may cause premature termination of the study.